Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.41 |
| ▸ | DRD3 | P35462 | 9/20 | 0.41 |
| ▸ | DRD1 | P21728 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31024630 | 1.00 | DRD2 (0.41) | DRD2DRD3DRD1SIGMAR1MAPT | |
| SCHEMBL21966300 | 1.00 | DRD2 (0.41) | DRD2DRD3DRD1SIGMAR1MAPT | |
| SCHEMBL31049497 | 1.00 | DRD2 (0.41) | DRD2DRD3DRD1SIGMAR1MAPT | |
| SCHEMBL15641002 | 0.89 | DRD2 (0.35) | DRD2DRD3DRD1SIGMAR1BRD4 | |
| SCHEMBL17005443 | 0.85 | SIGMAR1 (0.44) | DRD2DRD3DRD1SIGMAR1MAPT | |
| SCHEMBL31024632 | 0.84 | DRD4 (0.41) | SIGMAR1BRD4 | |
| SCHEMBL2795742 | 0.83 | MAPT (0.52) | DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL15935483 | 0.83 | MAPT (0.52) | DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL22034017 | 0.83 | MAPT (0.52) | DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL2795738 | 0.83 | MAPT (0.52) | DRD2DRD3SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315475-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | DRD2 3916/4885DRD3 3989/4885DRD1 3640/4885 |
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | SERPINB1, PREP, PRSS1 | DRD2 4539/4885DRD3 4157/4885DRD1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.